HER2‐targeted therapies, such as trastuzumab and pertuzumab, have been instrumental in treating HER2‐amplified breast and gastric cancers by blocking HER2 signaling and inhibiting tumor growth [376]. This evidence concerns the gene ERBB2 and neoplasm.